本文選題：慢性阻塞性肺疾病　切入點(diǎn)：肺部感染　出處：《中華醫(yī)院感染學(xué)雜志》2017年13期 　論文類型：期刊論文

【摘要】：目的探究慢性阻塞性肺疾病并發(fā)肺部感染患者血清白細(xì)胞介素-6(IL-6)、觸珠蛋白(HPT)、淀粉樣蛋白A(SAA)水平,為慢性阻塞性肺疾病并發(fā)肺部感染提供診斷依據(jù)。方法選取2014年1月-2016年1月醫(yī)院接受治療的354例慢性阻塞性肺疾病患者為研究對象,其中并發(fā)肺部感染的92例患者為A組,262例未發(fā)生肺部感染的患者為B組,選取354名健康體檢者為C組;對A組患者進(jìn)行菌落培養(yǎng)并鑒定肺部感染病原菌種類;采用酶聯(lián)免疫吸附試驗(yàn)對三組研究者血清白細(xì)胞介素-6進(jìn)行測定并加以比較;使用雙光徑免疫濁度分析儀檢測三組研究者觸珠蛋白以及淀粉樣蛋白A水平;將A組患者根據(jù)是否患有呼吸衰竭分為慢性阻塞性肺疾病非加重患者和加重患者,比較兩組患者以上指標(biāo)含量水平;運(yùn)用ROC曲線測定血清白細(xì)胞介素-6、觸珠蛋白以及淀粉樣蛋白A對慢性阻塞性肺疾病并發(fā)肺部感染的診斷價(jià)值。結(jié)果 A組的92例患者共檢出病原菌164株,其中革蘭陽性菌36株占22.0%、革蘭陰性菌107株占65.2%、真菌14株占8.6%、其他菌種7株占4.3%;A組患者血清IL-6含量為114.42±17.82ng/L、HPT含量為1.88±0.36g/L、SAA含量為271.05±22.45g/L,B組患者血清IL-6含量為83.46±15.59ng/L、HPT含量為1.56±0.24g/L、SAA含量為225.49±20.68g/L,C組研究者IL-6含量為31.03±19.71ng/L、HPT含量為0.89±0.21g/L、SAA含量為48.24±19.37g/L,三組數(shù)據(jù)比較差異具有統(tǒng)計(jì)學(xué)意義(P0.05);并發(fā)肺部感染的患者中,加重患者血清IL-6、HPT以及SAA水平均高于非加重患者。結(jié)論血清白細(xì)胞介素-6、觸珠蛋白以及淀粉樣蛋白A均可對慢性阻塞性肺疾病并發(fā)肺部感染進(jìn)行預(yù)測,臨床可加以控制。
[Abstract]:Objective to investigate the serum levels of interleukin-6 (IL-6) IL-6, haptoglobin (HPTT) and amyloid protein (Agna) in patients with chronic obstructive pulmonary disease (COPD) complicated with pulmonary infection. Methods 354 patients with chronic obstructive pulmonary disease (COPD) received hospital treatment from January 2014 to January 2016 were selected as subjects. Among them, 92 patients complicated with pulmonary infection were group A (262 patients without pulmonary infection) and 354 healthy persons (group C). The levels of serum interleukin-6 (IL-6) and amyloid A (amyloid A) in the three groups were measured by enzyme-linked immunosorbent assay (Elisa). The patients in group A were divided into two groups: chronic obstructive pulmonary disease (COPD) patients without exacerbation and patients with exacerbation according to whether they had respiratory failure, and the above indexes were compared between the two groups. The diagnostic value of serum interleukin-6 (IL-6), globin and amyloid A (amyloid A) in patients with chronic obstructive pulmonary disease (COPD) complicated with pulmonary infection was determined by ROC curve. Results in group A, 164 strains of pathogenic bacteria were detected in 92 patients with chronic obstructive pulmonary disease (COPD). Among them, 36 Gram-positive bacteria accounted for 22.0%, 107 Gram-negative bacteria accounted for 65.2, 14 fungi accounted for 8.6am, and other 7 strains accounted for 4.3A, the serum IL-6 content was 114.42 鹵17.82ng / L HPT 1.88 鹵0.36g / L LSAA = 271.05 鹵22.45g / L LSAA = 83.46 鹵15.59ng / L / L HPT = 1.56 鹵0.24g / L LSAA = 225.49 鹵20.68g / L LSAA = 225.49 鹵20.68g / L LSAA. The IL-6 content of the three groups was 31.03 鹵19.71 ng / L, 0.89 鹵0.21 g / L, 48.24 鹵19.37 g / L, respectively. The difference among the three groups was statistically significant (P 0.05). The serum levels of IL-6 HPT and SAA in patients with exacerbation were higher than those in patients without exacerbation. Conclusion Serum interleukin-6, globin and amyloid A can be used to predict pulmonary infection in patients with chronic obstructive pulmonary disease and can be controlled clinically.
【作者單位】： 湖北醫(yī)藥學(xué)院附屬人民醫(yī)院呼吸內(nèi)科;
【分類號(hào)】：R563

【參考文獻(xiàn)】

相關(guān)期刊論文 前6條

1 田斌;;老年重型顱腦損傷合并肺部感染患者血清CRP、PCT水平及意義[J];山東醫(yī)藥;2016年28期

2 金權(quán);周海英;胡志雄;;老年慢性阻塞性肺疾病合并肺部感染的病原菌分布情況及藥物敏感性分析[J];中國臨床醫(yī)學(xué);2014年06期

3 趙一文;陳灝;;老年慢性阻塞性肺疾病伴肺部感染患者營養(yǎng)不良的臨床特點(diǎn)及危險(xiǎn)因素分析[J];中華醫(yī)院感染學(xué)雜志;2014年07期

4 ;慢性阻塞性肺疾病診治指南(2013年修訂版)[J];中國醫(yī)學(xué)前沿雜志(電子版);2014年02期

5 李宏;陽甜;楊嵐;;慢性阻塞性肺疾病患者肺部感染血清炎性因子變化研究[J];中華醫(yī)院感染學(xué)雜志;2014年01期

6 朱亞彬,許建屏,劉志勇,楊丹寧,李旭東,李鴻雁;Off-pump coronary artery bypass grafting versus on-pumpcoronary artery bypass grafting: which is better in patients with chronic obstructive pulmonary disease?[J];Journal of Zhejiang University Science;2004年08期

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 陳群;聶署萍;吳愿如;;深圳某院住院患者多重耐藥菌感染臨床分布特點(diǎn)的研究[J];國際檢驗(yàn)醫(yī)學(xué)雜志;2017年14期

2 庾鳳娟;司徒瑞儒;張曉媚;何卓雄;;維持性血液透析患者感染的病原菌及其藥敏分析[J];中國現(xiàn)代藥物應(yīng)用;2017年14期

3 衛(wèi)軍;徐鶯;梅昕;萬向農(nóng);毛亦秋;;院內(nèi)疑似粘質(zhì)沙雷菌聚集性暴發(fā)標(biāo)準(zhǔn)化處置模式[J];中華災(zāi)害救援醫(yī)學(xué);2017年07期

4 袁天慧;陳孝銀;何偉明;董爾丹;孟慶峰;畢明剛;;溫病理論與感染/傳染性疾病:研究現(xiàn)狀及發(fā)展建議[J];中國科學(xué)基金;2017年04期

5 宋月蘭;王建兵;劉麗萍;;頭孢哌酮舒巴坦鈉在院內(nèi)感染應(yīng)用中的成本效益分析[J];中國生化藥物雜志;2017年07期

6 黃晶;王海鵬;劉燕瑜;崔璨;;環(huán)境清潔相關(guān)措施減少患者多藥耐藥菌定植感染研究進(jìn)展[J];中華醫(yī)院感染學(xué)雜志;2017年13期

7 劉香;顧玲莉;;多重耐藥菌感染干預(yù)項(xiàng)目的分析評(píng)價(jià)[J];國際檢驗(yàn)醫(yī)學(xué)雜志;2017年12期

8 王強(qiáng);趙淑慧;高瑛;張湛;郝佳;蘇志南;;中藥對常見耐藥菌生物被膜影響的研究進(jìn)展[J];中醫(yī)藥導(dǎo)報(bào);2017年12期

9 楊亞紅;張映華;蔡玲;胡蘭文;周W，

本文編號(hào)：1593903